GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy
Korean Firm Plans Trial Start Soon
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
You may also be interested in...
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.